|
21 Companies |
|
32 Products |
|
32 Products |
|
31 Mechanisms of Action |
|
0 Trials |
|
632 News |
|
| «123456789101112» |
- dexmedetomidine / Generic mfg.
Clinical: Dexmedetomidine in Seizure Patients (clinicaltrials.gov) - Jul 14, 2012
P1, N=16, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed
- lorazepam / Generic mfg.
Enrollment change: Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children. (clinicaltrials.gov) - Jul 8, 2012
P3, N=800, Terminated, Sponsor: University of Malawi College of Medicine
Recruiting --> Completed N=1200 --> 800
- ||||| zonisamide / Generic mfg.
New P4 trial, Head-to-Head: Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug (clinicaltrials.gov) - Jun 26, 2012
P4, N=200, Recruiting, Sponsor: Eisai Inc.
- ||||| topiramate / Generic mfg.
New P4 trial: First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients (clinicaltrials.gov) - Jun 24, 2012
P4, N=55, Completed, Sponsor: Johnson & Johnson Taiwan Ltd
- New P2 trial: Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants (clinicaltrials.gov) - Jun 18, 2012
P2, N=24, Recruiting, Sponsor: Children's Research Institute
- ||||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Enrollment closed: Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children (clinicaltrials.gov) - Jun 14, 2012
P3, N=252, Active, not recruiting, Sponsor: Bial - Portela C S.A.
N=1200 --> 800 Recruiting --> Active, not recruiting
- phenobarbital / Generic mfg.
Trial termination: PROPHENO: Prophylactic Phenobarbital After Neonatal Seizures (clinicaltrials.gov) - Jun 7, 2012
P4, N=13, Terminated, Sponsor: University of Rochester
Recruiting --> Active, not recruiting Recruiting --> Terminated; Inadequate rate of enrollment
- phenobarbital / Generic mfg.
Enrollment change: PROPHENO: Prophylactic Phenobarbital After Neonatal Seizures (clinicaltrials.gov) - Jun 7, 2012
P4, N=13, Terminated, Sponsor: University of Rochester
Recruiting --> Terminated; Inadequate rate of enrollment N=250 --> 13
- Enrollment change: A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures (clinicaltrials.gov) - May 24, 2012
P2b, N=0, Withdrawn, Sponsor: UCB, Inc.
N=250 --> 13 N=500 --> 0
- Enrollment change: Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy (clinicaltrials.gov) - May 24, 2012
P3, N=0, Withdrawn, Sponsor: UCB, Inc.
N=500 --> 0 N=1500 --> 0
- | levetiracetam / Generic mfg.
Enrollment change: An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures (clinicaltrials.gov) - May 23, 2012
P2, N=16, Completed, Sponsor: UCB Japan Co. Ltd.
N=1500 --> 0 N=10 --> 16
- | levetiracetam / Generic mfg.
Trial completion: An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures (clinicaltrials.gov) - May 23, 2012
P2, N=16, Completed, Sponsor: UCB Japan Co. Ltd.
N=10 --> 16 Recruiting --> Completed
- levetiracetam / Generic mfg.
Enrollment change: Levetiracetam in Treating Patients With Seizures Caused by Brain Metastases (clinicaltrials.gov) - May 16, 2012
P=N/A, N=0, Withdrawn, Sponsor: Northwestern University
Recruiting --> Completed N=30 --> 0
- || New P3 trial: Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients (clinicaltrials.gov) - May 16, 2012
P3, N=80, Recruiting, Sponsor: Sara Varea
- Trial initiation date: Stress Management Intervention for Living With Epilepsy (SMILE) (clinicaltrials.gov) - May 14, 2012
P2, N=100, Recruiting, Sponsor: Montefiore Medical Center
N=30 --> 0 Initiation date: Oct 2011 --> Jan 2012
- Enrollment open: Stress Management Intervention for Living With Epilepsy (SMILE) (clinicaltrials.gov) - May 14, 2012
P2, N=100, Recruiting, Sponsor: Montefiore Medical Center
Initiation date: Oct 2011 --> Jan 2012 Not yet recruiting --> Recruiting
- selurampanel (BGG492) / Novartis
Trial withdrawal: Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures (clinicaltrials.gov) - Apr 29, 2012
P2, N=0, Withdrawn, Sponsor: Novartis
Not yet recruiting --> Recruiting Terminated --> Withdrawn
- ||| lacosamide / Generic mfg.
Trial completion: Belgian Drug-utilization Study to Evaluate the Use of VIMPAT (clinicaltrials.gov) - Apr 22, 2012
P=N/A, N=192, Completed, Sponsor: UCB, Inc.
Terminated --> Withdrawn Active, not recruiting --> Completed
- ||| lacosamide / Generic mfg.
Trial completion: PASS: Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures (clinicaltrials.gov) - Apr 18, 2012
P=N/A, N=1005, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Fycompa (perampanel) / Eisai, Catalyst Pharma
Enrollment change: 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures (clinicaltrials.gov) - Apr 18, 2012
P2, N=108, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed N=192 --> 108
- Trial completion: Investigation on the Value of Bilateral Index (BIS) Monitoring for Magnetic Seizure Versus Electroconvulsive Therapy (clinicaltrials.gov) - Apr 14, 2012
P=N/A, N=20, Completed, Sponsor: University Hospital, Bonn
N=192 --> 108 Recruiting --> Completed
- Clinical: Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma (clinicaltrials.gov) - Apr 12, 2012
P=N/A, N=20, Recruiting, Sponsor: University of Alabama at Birmingham
- ||||| Vanquix (diazepam auto-injector) / Pfizer
Enrollment change: Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures. (clinicaltrials.gov) - Apr 10, 2012
P3, N=234, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Completed N=325 --> 234
- || Enrollment closed: PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study of PuLsE 1 (clinicaltrials.gov) - Apr 8, 2012
P=N/A, N=81, Active, not recruiting, Sponsor: Cyberonics, Inc.
N=325 --> 234 Recruiting --> Active, not recruiting
- ||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial initiation date: Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients (clinicaltrials.gov) - Mar 28, 2012
P4, N=100, Active, not recruiting, Sponsor: Bial - Portela C S.A.
Recruiting --> Active, not recruiting Initiation date: Aug 2009 --> Apr 2010
- Trial termination: METTLE: A Multicenter Study of Hippocampal Electrical Stimulation (HS, in Mesial Temporal Lobe Epilepsy (clinicaltrials.gov) - Mar 27, 2012
P3, N=8, Terminated, Sponsor: University of Calgary
Initiation date: Aug 2009 --> Apr 2010 Recruiting --> Terminated; insufficient enrolment
- Enrollment change: METTLE: A Multicenter Study of Hippocampal Electrical Stimulation (HS, in Mesial Temporal Lobe Epilepsy (clinicaltrials.gov) - Mar 27, 2012
P3, N=8, Terminated, Sponsor: University of Calgary
Recruiting --> Terminated; insufficient enrolment N=57 --> 8
- Enrollment closed: Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy (clinicaltrials.gov) - Mar 20, 2012
P1, N=20, Active, not recruiting, Sponsor: Instituto do Cerebro de Brasilia
N=57 --> 8 Recruiting --> Active, not recruiting
- Enrollment change: Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy. (clinicaltrials.gov) - Mar 18, 2012
P3, N=0, Withdrawn, Sponsor: UCB, Inc.
Recruiting --> Active, not recruiting N=500 --> 0
- ||| lacosamide / Generic mfg., fosphenytoin / Generic mfg.
Trial initiation date: Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures (clinicaltrials.gov) - Mar 14, 2012
P2, N=200, Recruiting, Sponsor: Aatif Husain
N=500 --> 0 Initiation date: Feb 2012 --> May 2012
- ||||||| clobazam / Generic mfg.
Trial completion: LGS: Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome (clinicaltrials.gov) - Mar 12, 2012
P3, N=267, Completed, Sponsor: Lundbeck LLC
Initiation date: Feb 2012 --> May 2012 Active, not recruiting --> Completed
- zonisamide / Generic mfg.
New P4 trial: A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures (clinicaltrials.gov) - Mar 5, 2012
P4, N=41, Terminated, Sponsor: Eisai Limited
- New P2 trial: IVIG Treatment for Refractory Immune-Related Adult Epilepsy (clinicaltrials.gov) - Mar 4, 2012
P2, N=20, Terminated, Sponsor: Emory University
- ||||||| rufinamide / Generic mfg.
Trial completion: A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304) (clinicaltrials.gov) - Mar 4, 2012
P3, N=66, Completed, Sponsor: Eisai Limited
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy (clinicaltrials.gov) - Mar 1, 2012
P4, N=30, Completed, Sponsor: Cyberonics, Inc.
Recruiting --> Completed Recruiting --> Completed
- levetiracetam / Generic mfg.
Enrollment change: TRACK: Prevention of Post-traumatic Seizures With Levetiracetam (clinicaltrials.gov) - Feb 29, 2012
P3, N=23, Terminated, Sponsor: Rennes University Hospital
Recruiting --> Completed N=600 --> 23
- levetiracetam / Generic mfg., carbamazepine / Generic mfg.
Trial completion: Photosensitivity Proof of Concept Trial (clinicaltrials.gov) - Feb 29, 2012
P2, N=6, Completed, Sponsor: The Epilepsy Study Consortium
N=600 --> 23 Active, not recruiting --> Completed
- ||| Trial completion: Putting Electroencephalography (EEG) in the Emergency Department (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=261, Completed, Sponsor: Bio-Signal Group Corp.
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
New P2 trial: Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures (clinicaltrials.gov) - Feb 5, 2012
P2, N=117, Active, not recruiting, Sponsor: Bial - Portela C S.A.
- | Fycompa (perampanel) / Eisai, Catalyst Pharma
New P2 trial: Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs (clinicaltrials.gov) - Feb 2, 2012
P2, N=48, Active, not recruiting, Sponsor: Eisai Inc.
- levetiracetam / Generic mfg.
Enrollment change: IV Levetiracetam for the Treatment of Neonatal Seizures: a Pharmacokinetic and Preliminary Efficacy and Safety Study (clinicaltrials.gov) - Feb 1, 2012
P1/2, N=18, Completed, Sponsor: Richard H. Haas
Recruiting --> Completed N=24 --> 18
- levetiracetam / Generic mfg.
Trial completion: IV Levetiracetam for the Treatment of Neonatal Seizures: a Pharmacokinetic and Preliminary Efficacy and Safety Study (clinicaltrials.gov) - Feb 1, 2012
P1/2, N=18, Completed, Sponsor: Richard H. Haas
N=24 --> 18 Recruiting --> Completed
- levetiracetam / Generic mfg.
New P1 trial: Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children (clinicaltrials.gov) - Jan 26, 2012
P1, N=144, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
- phenobarbital / Generic mfg.
Trial completion: Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients. (clinicaltrials.gov) - Jan 25, 2012
P=N/A, N=52, Completed, Sponsor: Yonsei University
Recruiting --> Completed Active, not recruiting --> Completed
- lacosamide / Generic mfg.
Trial termination: A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide (clinicaltrials.gov) - Jan 22, 2012
P=N/A, N=11, Terminated, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Recruiting --> Terminated; Lack of enrollement
- lacosamide / Generic mfg.
Enrollment change: A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide (clinicaltrials.gov) - Jan 22, 2012
P=N/A, N=11, Terminated, Sponsor: University of Alabama at Birmingham
Recruiting --> Terminated; Lack of enrollement N=52 --> 11
- Potiga (retigabine) / Bausch Health, GSK
Trial initiation date: Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304 (clinicaltrials.gov) - Jan 19, 2012
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
N=52 --> 11 Initiation date: Apr 2011 --> Aug 2011
- ||| Enrollment change: Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug (clinicaltrials.gov) - Jan 18, 2012
P4, N=141, Completed, Sponsor: GlaxoSmithKline
Initiation date: Apr 2011 --> Aug 2011 N=104 --> 141
- | brivaracetam / Generic mfg.
Enrollment change: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam (clinicaltrials.gov) - Jan 17, 2012
P3, N=108, Active, not recruiting, Sponsor: UCB, Inc.
N=104 --> 141 N=600 --> 108
- sertraline / Generic mfg.
Trial termination, HEOR: Depression and Health Outcomes in Refractory Epilepsy (clinicaltrials.gov) - Jan 12, 2012
P3, N=140, Terminated, Sponsor: Columbia University
N=600 --> 108 Active, not recruiting --> Terminated